Editas Medicine stockholders approve increase in authorized shares and amend 2015 Stock Incentive Plan at annual meeting

Editas Medicine, Inc.

Stockholders approved amendment to increase authorized common stock from 195M to 390M shares; total capital stock from 200M to 395M.
Stockholders approved amendment and restatement of 2015 Stock Incentive Plan, extending term to 10 years and eliminating evergreen provision.
Re-elected Jessica Hopfield, Ph.D., and David Scadden, M.D. as Class III directors until the 2028 annual meeting.
Advisory vote on executive compensation passed with ~60% for; one-year frequency for future say-on-pay votes approved.
Ratified Ernst & Young LLP as independent registered public accounting firm for fiscal year 2025.

item 5.02item 5.03item 5.07item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.